Skip to main content
Erschienen in: Neurocritical Care 1/2020

15.11.2019 | Review

Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU

verfasst von: Farwa Ali, Eelco F. Wijdicks

Erschienen in: Neurocritical Care | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Immune response against neuronal and glial cell surface and cytosolic antigens is an important cause of encephalitis. It may be triggered by activation of the immune system in response to an infection (para-infectious), cancer (paraneoplastic), or due to a patient’s tendency toward autoimmunity. Antibodies directed toward neuronal cell surface antigens are directly pathogenic, whereas antibodies with intracellular targets may become pathogenic if the antigen is transiently exposed to the cell surface or via activation of cytotoxic T cells. Immune-mediated encephalitis is well recognized and may require intensive care due to status epilepticus, need for invasive ventilation, or dysautonomia. Patients with immune-mediated encephalitis may become critically ill and display clinically complex and challenging to treat movement disorders in over 80% of the cases (Zhang et al. in Neurocrit Care 29(2):264–272, 2018). Treatment options include immunotherapy and symptomatic agents affecting dopamine or acetylcholine neurotransmission. There has been no prior published guidance for management of these movement disorders for the intensivist. Herein, we discuss the immune-mediated encephalitis most likely to cause critical illness, clinical features and mechanisms of movement disorders and propose a management algorithm.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dash D, Ihtisham K, Tripathi M, Tripathi M. Proportion and spectrum of movement disorders in adolescent and adult patients of autoimmune encephalitis of non-neoplastic aetiology. J Clin Neurosci. 2019;59:185–9.PubMedCrossRef Dash D, Ihtisham K, Tripathi M, Tripathi M. Proportion and spectrum of movement disorders in adolescent and adult patients of autoimmune encephalitis of non-neoplastic aetiology. J Clin Neurosci. 2019;59:185–9.PubMedCrossRef
2.
Zurück zum Zitat Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep. 2017;17(1):6.PubMedCrossRef Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep. 2017;17(1):6.PubMedCrossRef
3.
Zurück zum Zitat Duan B-C, Weng W-C, Lin K-L, et al. Variations of movement disorders in anti-N-methyl-d-aspartate receptor encephalitis: a nationwide study in Taiwan. Medicine. 2016;95(37):e4365.PubMedPubMedCentralCrossRef Duan B-C, Weng W-C, Lin K-L, et al. Variations of movement disorders in anti-N-methyl-d-aspartate receptor encephalitis: a nationwide study in Taiwan. Medicine. 2016;95(37):e4365.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013;28(4):543–7.PubMedCrossRef Baizabal-Carvallo JF, Stocco A, Muscal E, Jankovic J. The spectrum of movement disorders in children with anti-NMDA receptor encephalitis. Mov Disord. 2013;28(4):543–7.PubMedCrossRef
5.
Zurück zum Zitat Kleinig TJ, Thompson PD, Matar W, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord. 2008;23(9):1256–61.PubMedCrossRef Kleinig TJ, Thompson PD, Matar W, et al. The distinctive movement disorder of ovarian teratoma-associated encephalitis. Mov Disord. 2008;23(9):1256–61.PubMedCrossRef
6.
Zurück zum Zitat Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.PubMedPubMedCentralCrossRef Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Eskow Jaunarajs KL, Bonsi P, Chesselet MF, Standaert DG, Pisani A. Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol. 2015;127–128:91–107.PubMedCrossRef Eskow Jaunarajs KL, Bonsi P, Chesselet MF, Standaert DG, Pisani A. Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol. 2015;127–128:91–107.PubMedCrossRef
8.
Zurück zum Zitat Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Dystonia Study Group. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003;18(3):303–12.PubMedCrossRef Comella CL, Leurgans S, Wuu J, Stebbins GT, Chmura T. Dystonia Study Group. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003;18(3):303–12.PubMedCrossRef
9.
Zurück zum Zitat Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135(Pt 11):3453–68.PubMedCrossRef Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135(Pt 11):3453–68.PubMedCrossRef
10.
Zurück zum Zitat Davies G, Irani SR, Coltart C, et al. Anti-N-methyl-d-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med. 2010;38(2):679–82.PubMedCrossRef Davies G, Irani SR, Coltart C, et al. Anti-N-methyl-d-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med. 2010;38(2):679–82.PubMedCrossRef
11.
Zurück zum Zitat Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.PubMedPubMedCentralCrossRef Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.PubMedPubMedCentralCrossRef
12.
Zurück zum Zitat Sutter R, Ristic A, Rüegg S, Fuhr P. Myoclonus in the critically ill: diagnosis, management, and clinical impact. Clin Neurophysiol. 2016;127(1):67–80.PubMedCrossRef Sutter R, Ristic A, Rüegg S, Fuhr P. Myoclonus in the critically ill: diagnosis, management, and clinical impact. Clin Neurophysiol. 2016;127(1):67–80.PubMedCrossRef
13.
Zurück zum Zitat Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. 2014;82(17):1521–8.PubMedCrossRef Balint B, Jarius S, Nagel S, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. 2014;82(17):1521–8.PubMedCrossRef
14.
Zurück zum Zitat Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol. 2015;15(286):86–92.CrossRef Panzer JA, Anand R, Dalmau J, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol. 2015;15(286):86–92.CrossRef
17.
Zurück zum Zitat Herken J, Prüss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry. 2017;16(8):25. Herken J, Prüss H. Red flags: clinical signs for identifying autoimmune encephalitis in psychiatric patients. Front Psychiatry. 2017;16(8):25.
18.
Zurück zum Zitat Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135(Pt 5):1606–21.PubMedCrossRef Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135(Pt 5):1606–21.PubMedCrossRef
19.
Zurück zum Zitat Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture. Neurology. 2016;87(23):2471–82.PubMedPubMedCentralCrossRef Dalmau J. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias Lecture. Neurology. 2016;87(23):2471–82.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Varley JA, Webb AJS, Balint B, et al. The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry. 2019;90(6):724–6.PubMedCrossRef Varley JA, Webb AJS, Balint B, et al. The Movement disorder associated with NMDAR antibody-encephalitis is complex and characteristic: an expert video-rating study. J Neurol Neurosurg Psychiatry. 2019;90(6):724–6.PubMedCrossRef
21.
Zurück zum Zitat van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290–301.PubMedCrossRef van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol. 2017;13(5):290–301.PubMedCrossRef
22.
Zurück zum Zitat Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017;88(4):353–61.PubMedCrossRef Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017;88(4):353–61.PubMedCrossRef
23.
Zurück zum Zitat Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry. 2018;89(5):526–34.PubMedCrossRef Binks SNM, Klein CJ, Waters P, Pittock SJ, Irani SR. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry. 2018;89(5):526–34.PubMedCrossRef
24.
Zurück zum Zitat Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900.PubMedCrossRef Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol. 2011;69(5):892–900.PubMedCrossRef
26.
Zurück zum Zitat Iyer RS, Ramakrishnan TCR, Karunakaran Shinto A, Kamaleshwaran KK. Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement. Epilepsy Behav Case Rep. 2017;8:47–50.PubMedPubMedCentralCrossRef Iyer RS, Ramakrishnan TCR, Karunakaran Shinto A, Kamaleshwaran KK. Faciobrachial dystonic seizures result from fronto-temporo-basalganglial network involvement. Epilepsy Behav Case Rep. 2017;8:47–50.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Striano P. Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol. 2011;70(1):179–80 author reply 180.PubMedCrossRef Striano P. Faciobrachial dystonic attacks: seizures or movement disorder? Ann Neurol. 2011;70(1):179–80 author reply 180.PubMedCrossRef
28.
Zurück zum Zitat Damato V, Balint B, Kienzler A-K, Irani SR. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord. 2018;33(9):1376–89.PubMedPubMedCentralCrossRef Damato V, Balint B, Kienzler A-K, Irani SR. The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disorders. Mov Disord. 2018;33(9):1376–89.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178–92.PubMedPubMedCentralCrossRef Carvajal-González A, Leite MI, Waters P, et al. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain. 2014;137(Pt 8):2178–92.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Balint B, Vincent A, Meinck H-M, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain. 2018;141(1):13–36.PubMedCrossRef Balint B, Vincent A, Meinck H-M, Irani SR, Bhatia KP. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology. Brain. 2018;141(1):13–36.PubMedCrossRef
31.
Zurück zum Zitat Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders—new insights. Curr Opin Neurol. 2016;29(4):496–506.PubMedCrossRef Balint B, Bhatia KP. Stiff person syndrome and other immune-mediated movement disorders—new insights. Curr Opin Neurol. 2016;29(4):496–506.PubMedCrossRef
32.
Zurück zum Zitat Werner C, Pauli M, Doose S, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365–79.PubMedCrossRef Werner C, Pauli M, Doose S, et al. Human autoantibodies to amphiphysin induce defective presynaptic vesicle dynamics and composition. Brain. 2016;139(Pt 2):365–79.PubMedCrossRef
33.
34.
Zurück zum Zitat Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(Pt 5):1622–38.PubMedCrossRef Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain. 2012;135(Pt 5):1622–38.PubMedCrossRef
35.
Zurück zum Zitat Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf). 2016;216(1):90–100.CrossRef Cunningham MW, Cox CJ. Autoimmunity against dopamine receptors in neuropsychiatric and movement disorders: a review of Sydenham chorea and beyond. Acta Physiol (Oxf). 2016;216(1):90–100.CrossRef
36.
Zurück zum Zitat Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS ONE. 2013;8(9):e73516.PubMedPubMedCentralCrossRef Ben-Pazi H, Stoner JA, Cunningham MW. Dopamine receptor autoantibodies correlate with symptoms in Sydenham’s chorea. PLoS ONE. 2013;8(9):e73516.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Church AJ, Dale RC, Giovannoni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child. 2004;89(7):611–4.PubMedPubMedCentralCrossRef Church AJ, Dale RC, Giovannoni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child. 2004;89(7):611–4.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Carecchio M, Cantello R, Comi C. Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage. J Immunol Res. 2014;13(2014):239398. Carecchio M, Cantello R, Comi C. Revisiting the molecular mechanism of neurological manifestations in antiphospholipid syndrome: beyond vascular damage. J Immunol Res. 2014;13(2014):239398.
39.
Zurück zum Zitat Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical characteristics and prognosis of severe anti-N-methyl-d-aspartate receptor encephalitis patients. Neurocrit Care. 2018;29(2):264–72.PubMedCrossRef Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical characteristics and prognosis of severe anti-N-methyl-d-aspartate receptor encephalitis patients. Neurocrit Care. 2018;29(2):264–72.PubMedCrossRef
40.
Zurück zum Zitat Harutyunyan G, Hauer L, Dünser MW, et al. Risk factors for intensive care unit admission in patients with autoimmune encephalitis. Front Immunol. 2017;28(8):835.CrossRef Harutyunyan G, Hauer L, Dünser MW, et al. Risk factors for intensive care unit admission in patients with autoimmune encephalitis. Front Immunol. 2017;28(8):835.CrossRef
41.
Zurück zum Zitat Cohen J, Sotoca J, Gandhi S, et al. Autoimmune encephalitis: a costly condition. Neurology. 2019;92(9):e964–e972.PubMed Cohen J, Sotoca J, Gandhi S, et al. Autoimmune encephalitis: a costly condition. Neurology. 2019;92(9):e964–e972.PubMed
42.
Zurück zum Zitat Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord. 2017;28(4):10.CrossRef Termsarasab P, Frucht SJ. Dystonic storm: a practical clinical and video review. J Clin Mov Disord. 2017;28(4):10.CrossRef
43.
Zurück zum Zitat McKeon A. The importance of early and sustained treatment of a common autoimmune encephalitis. Lancet Neurol. 2013;12(2):123–5.PubMedCrossRef McKeon A. The importance of early and sustained treatment of a common autoimmune encephalitis. Lancet Neurol. 2013;12(2):123–5.PubMedCrossRef
44.
Zurück zum Zitat Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348–56.PubMedCrossRef Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain. 2018;141(2):348–56.PubMedCrossRef
46.
Zurück zum Zitat Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013;154(3):993–1007.PubMedCrossRef Vandevyver S, Dejager L, Tuckermann J, Libert C. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology. 2013;154(3):993–1007.PubMedCrossRef
47.
Zurück zum Zitat Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–9.PubMedCrossRef Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology—mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80–9.PubMedCrossRef
48.
Zurück zum Zitat Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300.PubMedPubMedCentralCrossRef Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76(3):294–300.PubMedPubMedCentralCrossRef
49.
Zurück zum Zitat Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76(2):168–84.PubMedPubMedCentralCrossRef Irani SR, Gelfand JM, Al-Diwani A, Vincent A. Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms. Ann Neurol. 2014;76(2):168–84.PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366–70.PubMedCrossRef Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology. 2017;88(4):366–70.PubMedCrossRef
51.
Zurück zum Zitat Lee W-J, Lee S-T, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824–32.PubMedPubMedCentralCrossRef Lee W-J, Lee S-T, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13(4):824–32.PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Shin Y-W, Lee S-T, Park K-I, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.PubMed Shin Y-W, Lee S-T, Park K-I, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord. 2018;11:1756285617722347.PubMed
53.
Zurück zum Zitat Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics. 2014;11(1):208–12.PubMedCrossRef Frucht SJ. Treatment of movement disorder emergencies. Neurotherapeutics. 2014;11(1):208–12.PubMedCrossRef
54.
Zurück zum Zitat Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Arch Neurol. 2011;68(5):567–72.PubMedCrossRef Robottom BJ, Weiner WJ, Factor SA. Movement disorders emergencies. Part 1: Hypokinetic disorders. Arch Neurol. 2011;68(5):567–72.PubMedCrossRef
55.
Zurück zum Zitat Robottom BJ, Factor SA, Weiner WJ. Movement disorders emergencies. Part 2: hyperkinetic disorders. Arch Neurol. 2011;68(6):719–24.PubMedCrossRef Robottom BJ, Factor SA, Weiner WJ. Movement disorders emergencies. Part 2: hyperkinetic disorders. Arch Neurol. 2011;68(6):719–24.PubMedCrossRef
56.
Zurück zum Zitat Schaefer SM, Rostami R, Greer DM. Movement disorders in the intensive care unit. Semin Neurol. 2016;36(6):607–14.PubMedCrossRef Schaefer SM, Rostami R, Greer DM. Movement disorders in the intensive care unit. Semin Neurol. 2016;36(6):607–14.PubMedCrossRef
57.
Zurück zum Zitat Hughes JD, Rabinstein AA. Early diagnosis of paroxysmal sympathetic hyperactivity in the ICU. Neurocrit Care. 2014;20(3):454–9.PubMedCrossRef Hughes JD, Rabinstein AA. Early diagnosis of paroxysmal sympathetic hyperactivity in the ICU. Neurocrit Care. 2014;20(3):454–9.PubMedCrossRef
58.
Zurück zum Zitat Relja M, Miletić V. When movement disorders hurt: addressing pain in hyperkinetic disorders. Parkinsonism Relat Disord. 2017;44:110–3.PubMedCrossRef Relja M, Miletić V. When movement disorders hurt: addressing pain in hyperkinetic disorders. Parkinsonism Relat Disord. 2017;44:110–3.PubMedCrossRef
59.
Zurück zum Zitat Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79–92.PubMedCrossRef Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol. 2017;82(1):79–92.PubMedCrossRef
60.
Zurück zum Zitat Mittal MK, Rabinstein AA, Hocker SE, Pittock SJ, Wijdicks EFM, McKeon A. Autoimmune encephalitis in the ICU: analysis of phenotypes, serologic findings, and outcomes. Neurocrit Care. 2016;24(2):240–50.PubMedCrossRef Mittal MK, Rabinstein AA, Hocker SE, Pittock SJ, Wijdicks EFM, McKeon A. Autoimmune encephalitis in the ICU: analysis of phenotypes, serologic findings, and outcomes. Neurocrit Care. 2016;24(2):240–50.PubMedCrossRef
61.
Zurück zum Zitat Liu H, Jian M, Liang F, Yue H, Han R. Anti-N-methyl-d-aspartate receptor encephalitis associated with an ovarian teratoma: two cases report and anesthesia considerations. BMC Anesthesiol. 2015;16(15):150.CrossRef Liu H, Jian M, Liang F, Yue H, Han R. Anti-N-methyl-d-aspartate receptor encephalitis associated with an ovarian teratoma: two cases report and anesthesia considerations. BMC Anesthesiol. 2015;16(15):150.CrossRef
62.
Zurück zum Zitat Solt K, Eger EI, Raines DE. Differential modulation of human N-methyl-d-aspartate receptors by structurally diverse general anesthetics. Anesth Analg. 2006;102(5):1407–11.PubMedCrossRef Solt K, Eger EI, Raines DE. Differential modulation of human N-methyl-d-aspartate receptors by structurally diverse general anesthetics. Anesth Analg. 2006;102(5):1407–11.PubMedCrossRef
63.
Zurück zum Zitat Hollman JH, Brey RH, Bang TJ, Kaufman KR. Does walking in a virtual environment induce unstable gait? An examination of vertical ground reaction forces. Gait Posture. 2007;26(2):289–94.PubMedCrossRef Hollman JH, Brey RH, Bang TJ, Kaufman KR. Does walking in a virtual environment induce unstable gait? An examination of vertical ground reaction forces. Gait Posture. 2007;26(2):289–94.PubMedCrossRef
64.
Zurück zum Zitat Sonner JM, Zhang Y, Stabernack C, Abaigar W, Xing Y, Laster MJ. GABA(A) receptor blockade antagonizes the immobilizing action of propofol but not ketamine or isoflurane in a dose-related manner. Anesth Analg. 2003;96(3):706–12 table of contents.PubMed Sonner JM, Zhang Y, Stabernack C, Abaigar W, Xing Y, Laster MJ. GABA(A) receptor blockade antagonizes the immobilizing action of propofol but not ketamine or isoflurane in a dose-related manner. Anesth Analg. 2003;96(3):706–12 table of contents.PubMed
65.
Zurück zum Zitat Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ. Propofol inhibits phosphorylation of N-methyl-d-aspartate receptor NR1 subunits in neurons. Anesthesiology. 2006;104(4):763–9.PubMedCrossRef Kingston S, Mao L, Yang L, Arora A, Fibuch EE, Wang JQ. Propofol inhibits phosphorylation of N-methyl-d-aspartate receptor NR1 subunits in neurons. Anesthesiology. 2006;104(4):763–9.PubMedCrossRef
66.
Zurück zum Zitat Kozinn J, Mao L, Arora A, Yang L, Fibuch EE, Wang JQ. Inhibition of glutamatergic activation of extracellular signal-regulated protein kinases in hippocampal neurons by the intravenous anesthetic propofol. Anesthesiology. 2006;105(6):1182–91.PubMedCrossRef Kozinn J, Mao L, Arora A, Yang L, Fibuch EE, Wang JQ. Inhibition of glutamatergic activation of extracellular signal-regulated protein kinases in hippocampal neurons by the intravenous anesthetic propofol. Anesthesiology. 2006;105(6):1182–91.PubMedCrossRef
67.
Zurück zum Zitat Lapébie F-X, Kennel C, Magy L, et al. Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol. 2014;16(14):5.CrossRef Lapébie F-X, Kennel C, Magy L, et al. Potential side effect of propofol and sevoflurane for anesthesia of anti-NMDA-R encephalitis. BMC Anesthesiol. 2014;16(14):5.CrossRef
68.
Zurück zum Zitat Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122(4):448–59.PubMedPubMedCentralCrossRef Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122(4):448–59.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.PubMedPubMedCentralCrossRef Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56(8):893–913.PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci. 2011;31(44):15727–31.PubMedPubMedCentralCrossRef Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci. 2011;31(44):15727–31.PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Seifi A, Kitchen DL. Management of dyskinesia in anti-NMDAR encephalitis with tramadol. Clin Neurol Neurosurg. 2016;147:105–7.PubMedCrossRef Seifi A, Kitchen DL. Management of dyskinesia in anti-NMDAR encephalitis with tramadol. Clin Neurol Neurosurg. 2016;147:105–7.PubMedCrossRef
73.
Zurück zum Zitat Potschka H, Friderichs E, Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000;131(2):203–12.PubMedPubMedCentralCrossRef Potschka H, Friderichs E, Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol. 2000;131(2):203–12.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol. 2016;58(4):376–84.PubMedCrossRef Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol. 2016;58(4):376–84.PubMedCrossRef
75.
Zurück zum Zitat Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–70.PubMedCrossRef Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461–70.PubMedCrossRef
76.
Zurück zum Zitat Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487–504.PubMedCrossRef Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487–504.PubMedCrossRef
77.
Zurück zum Zitat Peckham AM, Nicewonder JA. VMAT2 inhibitors for tardive dyskinesia-practice implications. J Pharm Pract. 2018;1:897190018756512. Peckham AM, Nicewonder JA. VMAT2 inhibitors for tardive dyskinesia-practice implications. J Pharm Pract. 2018;1:897190018756512.
78.
Zurück zum Zitat Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017;18(12):1279–87.PubMedCrossRef Seeberger LC, Hauser RA. Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother. 2017;18(12):1279–87.PubMedCrossRef
79.
Zurück zum Zitat Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;1(147):84–8.CrossRef Jankovic J. An update on new and unique uses of botulinum toxin in movement disorders. Toxicon. 2018;1(147):84–8.CrossRef
80.
Zurück zum Zitat Hallett M. Mechanism of action of botulinum neurotoxin: unexpected consequences. Toxicon. 2018;1(147):73–6.CrossRef Hallett M. Mechanism of action of botulinum neurotoxin: unexpected consequences. Toxicon. 2018;1(147):73–6.CrossRef
82.
Zurück zum Zitat Mohammad SS, Dale RC. Principles and approaches to the treatment of immune-mediated movement disorders. Eur J Paediatr Neurol. 2018;22(2):292–300.PubMedCrossRef Mohammad SS, Dale RC. Principles and approaches to the treatment of immune-mediated movement disorders. Eur J Paediatr Neurol. 2018;22(2):292–300.PubMedCrossRef
83.
Metadaten
Titel
Treatment of Movement Disorder Emergencies in Autoimmune Encephalitis in the Neurosciences ICU
verfasst von
Farwa Ali
Eelco F. Wijdicks
Publikationsdatum
15.11.2019
Verlag
Springer US
Erschienen in
Neurocritical Care / Ausgabe 1/2020
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-019-00875-5

Weitere Artikel der Ausgabe 1/2020

Neurocritical Care 1/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.